Dupilumab efficacy and biomarkers in chronic rhinosinusitis with nasal polyps: Association between dupilumab treatment effect on nasal polyp score and biomarkers of type 2 inflammation in patients with chronic rhinosinusitis with nasal polyps in the phase 3 SINUS-24 and SINUS-52 trials.

Abstract

SUPPLEMENTARY TABLE 1. Demographics and baseline disease characteristics and biomarkers (SINUS-24/SINUS-52; pooled ITT population) SUPPLEMENTARY TABLE 2. Correlations between NPS and type 2 biomarker levels at baseline SUPPLEMENTARY FIGURE 1. Scatterplots of relationship between change from baseline in NPS and change in (A) nasal periostin and (B) nasal eotaxin-3 at Week 24 (SINUS-52), (C) serum periostin, (D) serum eotaxin-3, and (E) serum TARC at Week 52 in SINUS-52 (observed values; ITT population) Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.